Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +0.16%62 Days Inventory is 32.01 as of Mar. 2026, which is 23% below its 10-year median of 41.53. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円694.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 178 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 74.72% on this metric.
The historical rank and industry rank for Human Metabolome Technologies's Days Inventory or its related term are showing as below:
TSE:6090'
s Days Inventory Range Over the Past 10 Years
Min: 24.22 Med: 41.53 Max: 75.39
Current: 30.66
During the past 13 years, Human Metabolome Technologies's highest Days Inventory was 75.39. The lowest was 24.22. And the median was 41.53.
TSE:6090's Days Inventory is ranked better than 74.72% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.595
vs TSE:6090: 30.66
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Human Metabolome Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Human Metabolome Technologies's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.10.
Human Metabolome Technologies (TSE:6090) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Human Metabolome Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Human Metabolome Technologies's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Human Metabolome Technologies Days Inventory Related Terms
Human Metabolome Technologies Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Days Inventory Chart
TSE:6090 vs TMO, DHR, NTRA: Days Inventory Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Days Inventory of 32.01 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Human Metabolome Technologies and its competitors. This is 23% below median its historical median of 41.53. Over the past decade, Human Metabolome Technologies' Days Inventory has ranged from 24.22 to 75.39. According to the industry distribution chart, Human Metabolome Technologies ranks #45 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 25.3%.
Is Human Metabolome Technologies' Days Inventory too high?
Human Metabolome Technologies' current Days Inventory of 32.01 is 23% below median its 10-year median of 41.53. Over the past 10 years, this metric has ranged from a low of 24.22 to a high of 75.39. The Medical Diagnostics & Research industry median Days Inventory is 68.60. Human Metabolome Technologies' value of 32.01 is 53.3% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #45 out of 178 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #45 out of 178 companies for Days Inventory. This puts Human Metabolome Technologies in the upper half of its industry. The industry median Days Inventory is 68.60. Human Metabolome Technologies' value of 32.01 is 53.3% below this benchmark. Historically, Human Metabolome Technologies' own Days Inventory has ranged from 24.22 to 75.39 over the past decade. While the company's 10-year median is 41.53 vs. the industry median of 68.60, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.60, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Days Inventory of 32.01 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Days Inventory is 32.01, which is 23% below median its own 10-year median of 41.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円694.14, compared to a current price of 円626.00 — trading 9.8% below its estimated fair value. The current Days Inventory is 32.01, which is 23% below median its 10-year median of 41.53 and 53.3% below the Medical Diagnostics & Research industry median of 68.60. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Days Inventory is 32.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円626.00 is trading 9.8% below its estimated GF Value™ of 円694.14.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
Days Inventory: 32.01 (23% below median its 10-year median of 41.53)
GF Value™: 円694.14 vs. price of 円626.00 (9.8% below fair value)
Industry Position: 53.3% below the Medical Diagnostics & Research median (#45 of 178)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
